Deel 2 | Diabetesverwikkelingen
Behandeling en preventie van complicaties

De Wereldgezondheidsorganisatie voorspelt dat er wereldwijd 300 miljoen diabetici zullen zijn tegen 2025. Diabetes verhoogt een aantal risico’s op gezondheidsgebied: diabetescomplicaties zijn verantwoordelijk voor veel last, pijn en verlies aan levenskwaliteit voor de diabetespatiënten, en voor zeer hoge kosten voor de gezondheidszorg. Er is een directe relatie tussen de glycemiecontrole op het parcours van de diabetespatiënt en de latere zorgkosten!

Beste bezoeker, u heeft geen toegang.

Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.

U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!

Auteur

Lidy Gallant

Trefwoorden:

Figuren

Verschenen in

Referenties

  1. Franciosi M et al. Costs of treatment and complications of adult type 1 diabetes. Nutr Metab Cardiovasc Dis. 2012 Jun 29. [Epub ahead of print]

  2. Menzin J et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010 May;16(4):264-75.

  3. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann N Y Acad Sci. 2005 Jun;1043:440-51.

  4. Dandona P et al. Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. EMM 2010; 42(4):245.

  5. Sies H et al. Nutritional, Dietary and Postprandial Oxidative Stress. J. Nutr. 2005; 135:969-972

  6. Lagani V et al. A systematic review of predictive risk models for diabetes complications based on large scale clinical studies. J Diabetes Complications. 2012 S1056-8727(12)00330-3.

  7. Thomas A, Heinemann L. Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study. J Diabetes Sci Technol. 2012 May 1;6(3):572-80.

  8. Ceriello A et al. Is It Time to Treat? Perspectives in Diabetes. Diabetes 2005; 54:1-7.

  9. Farvid MS, Homayouni F, Amiri Z, Adelmanesh F. Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation. Diabetes Res Clin Pract. 2011 Apr 13. [Epub ahead of print]

  10. Farvid MS, Jalali M, Siassi F, Hosseini M. Source Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care. 2005 Oct;28(10):2458-64.

  11. Edeas M, Attaf D, Mailfert AS, Nasu M, Joubet R. Maillard reaction, mitochondria and oxidative stress: potential role of antioxidants. Pathol Biol (Paris). 2010 Jun;58(3):220-5.

  12. Ceriello A. New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy. Diabetes Care 2003; 26(5):1589-1596

  13. Andersen ME et al. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol. 2010 April 1; 244(1): 77–83.

  14. Babu PV, Si H, Liu D. Epigallocatechin gallate reduces vascular inflammation in db/db mice possibly through an NF-κB-mediated mechanism. Mol Nutr Food Res. 2012 Sep;56(9):1424-32.

  15. Babu PV, Si H, Fu Z, Zhen W, Liu D. Genistein prevents hyperglycemia-induced monocyte adhesion to human aortic endothelial cells through preservation of the cAMP signaling pathway and ameliorates vascular inflammation in obese diabetic mice. J Nutr. 2012 Apr;142(4):724-30.

  16. Dasgupta A, Sarma D, Saikia UK. Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012 Nov;16(6):1000-3.

  17. Tahergorabi Z, Khazaei M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med. 2012 Dec;3(12):827-38.

  18. Bianchi C, Del Prato S. Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials. Rev Diabet Stud. 2011 Fall;8(3):432-40.

  19. Dailey G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin Ther. 2011 Jun;33(6):665-78.

  20. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012 Jun;14 Suppl 1:S68-74.

  21. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol. 2009 Mar;156(5):713-27.

  22. Cheng X, Siow RC, Mann GE. Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway. Antioxid Redox Signal. 2011 Feb 1;14(3):469-87.

  23. Nys M. Co-enzym Q10, Diabetes, obesitas en andere pathologieën. AT&A 2011; 4:17-21.

  24. Shia TJ, Hökfelt TGM et al. Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db−/db− mouse, a type 2 diabetes model. PNAS 2013; 110(2) 690-695

  25. Pruimboom L. De vergeten functie van de pancreas. Syllabus voordrachten voor Van Nature, mei-juni 2010.

  26. Kota SK et al. Aberrant angiogenesis: The gateway to diabetic complications. Indian J Endocrinol Metab. 2012 Nov;16(6):918-30.

  27. Weintraub NL. Impaired hypoxic coronary vasodilation and ATP-sensitive potassium channel function: a manifestation of diabetic microangiopathy in humans? Circ Res. 2003 Feb 7;92(2):127-9.

  28. Miura H, Wachtel RE, Loberiza FR Jr, Saito T, Miura M, Nicolosi AC, Gutterman DD. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels.Circ Res 2003 Feb 7;92(2):151-8

  29. Bordier L, Bauduceau B. Glycemic targets and cardiovascular morbi-mortality. Presse Med. 2012; S0755-4982(12)00617-3.

  30. Hsieh TC, Lu X, Wang Z, Wu JM. Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Med Chem 2: 275–285, 2006.

  31. Ungvari Z et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H18-24.

  32. Chen CY, Jang JH, Li MH, Surh YJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 331: 993–1000, 2005.

  33. Kode A et al. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress. Am J Physiol Lung Cell Mol Physiol 294: L478–L488, 2008.

  34. Spanier G et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60, Suppl 4: 111–116, 2009.

  35. Soufi FG et al. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys. 2012 Dec;31(4):431-8.

  36. Turan B, Tuncay E, Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr. 2012 Apr;44(2):281-96.

  37. Akar F et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther. 2011; 25(2):119-31.

  38. Soufi FG et al. Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocr Regul. 2012 Apr;46(2):83-90.

  39. Babu PV, Si H, Liu D. Epigallocatechin gallate reduces vascular inflammation in db/db mice possibly through an NF-κB-mediated mechanism. Mol Nutr Food Res. 2012 Sep;56(9):1424-32.

  40. Gresele P et al. Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent. Diabetes Care 2010; 33(6):1262-1268

  41. Koláček M, Muchová J, Vranková S, Jendeková L, Pecháňová O, Uličná O, Watala C, Duračková Z.Effect of natural polyphenols, pycnogenol® on superoxide dismutase and nitric oxide synthase in diabetic rats.Prague Med Rep. 2010;111(4):279-88.

  42. Lee HH, Kim KJ, Lee OH, Lee BY. Effect of pycnogenol on glucose transport in mature 3T3-L1 adipocytes.Phytother Res. 2010 Aug;24(8):1242-9.

  43. Tankova T et al. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study. Rom J Intern Med. 2004;42(2):457-64.

  44. Karpova IA et al. Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs. Ter Arkh. 2005;77(10):15-9.

  45. Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother. 2008 Nov;42(11):1686-91.

  46. Kulkarni SK, Dhir A. Curcumin in Neurological Disorders. Indian J Pharm Sci. 2010 Mar-Apr; 72(2): 149–154

  47. Kulkarni SK, Dhir A. An overview of curcumin in neurological disorders. Indian J Pharm Sci. 2010 Mar;72(2):149-54.

  48. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res. 2007 Mar;21(3):278-83.

  49. Kuhad A, Sharma S, Chopra K. Lycopene attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pain. 2008 Jul;12(5):624-32.

  50. Peters TJ et al. Treatment of alcoholic polyneuropathy with vitamin B complex: a randomised controlled trial.Alcohol Alcohol. 2006 Nov-Dec;41(6):636-42.

  51. Jianbo L et al. Diabetes Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes. Res Clin Pract. 2011 Apr 8. [Epub ahead of print]

  52. Dobryniewski J, Zwierz K et al. The gamma-linolenic acid (GLA)--the therapeutic value. Przegl Lek. 2007;64(2):100-2.

  53. Horrobin DF. The use of gamma-linolenic acid in diabetic neuropathy. Agents Actions Suppl. 1992;37:120-44.

  54. Tesfaye et al. Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management. Diabetes Metab Res Rev. 2011 Jun 21.

  55. Webster LR et al. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract. 2011 May 23. [Epub ahead of print]

  56. Bril V et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011 Apr;3(4):345-52, 352.e1-21.

  57. Zillox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011 Apr;13(2):143-59.

  58. Chakkarwar VA. Smoking in diabetic nephropathy: sparks in the fuel tank?

  59. Bregovskii et al. Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs. Ter Arkh 2005;77(10):15-9.

  60. Tankova T et al. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study).Rom J Intern Med 2004;42(2):457-64

  61. Zavrelova H, Dekker JM et al. Progression and Regression: Distinct Developmental Patterns of Diabetic Retinopathy in Patients With Type 2 Diabetes Treated in the Diabetes Care System West-Friesland, the Netherlands. Diabetes Care April 2011 34:867-872

  62. Hirai FE, Tielsch JM, Klein BE, Klein R. Ten-year change in self-rated quality of life in a type 1 diabetes population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Qual Life Res. 2012 Aug 8. [Epub ahead of print]

  63. Babizhayev MA, Yegorov YE. Reactive Oxygen Species and the Aging Eye: …A Novel Platform of Mitochondria-Targeted Antioxidants… Am J Ther 2010 Oct 22. [Epub ahead of print]

  64. Steigerwalt R et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009 Dec;25(6):537-40.

  65. Schönlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review.Int Ophthalmol. 2001;24(3):161-71.

  66. Spadea L, Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol.Phytother Res. 2001 May;15(3):219-23.

  67. Brazionis L et al. Homocysteine and diabetic retinopathy. Diabetes Care. 2008 Jan;31(1):50-6. Epub 2007 Sep 26.

  68. Meeusen J. Thiamine: B-vitamine numero één. AT&A 2014; 3:24-29.

  69. Ware, M. A.; Wang, T.; Shapiro, S.; Robinson, A.; Ducruet, T.; Huynh, T.; Gamsa, A.; Bennett, G. J.; Collet, J-P. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial". Can Med Assoc J 2010; 182 (14): E694–E701.

  70. Keppel Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 2012; 5:437-42.

  71. Jan M. Keppel Hesselink. New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide". The Open Pain Journal 2012; 5: 12–23.

  72. Palmitoylethanolamide, effectieve lichaamseigen pijnstiller en ontstekingsremmer. AT&A. 2014; 15:54-58

  73. Darmani, N. A.; Izzo, A. A.; Degenhardt, B.; Valenti, M.; Scaglione, G.; Capasso, R.; Sorrentini, I.; Di Marzo, V. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology 2005; 48 (8): 1154–1163.

  74. Negi, G.; Kumar, A.; Sharma, S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: Effects on NF-kappaB and Nrf2 cascades. J. Pineal Res2011, 50, 124–131.

  75. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005;7:293-318.

  76. Babizhayev MA. Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases. Drug Metabol Drug Interact. 2009;24(2-4):275-323.

  77. Kim YJ, Kim YA, Yokozawa T. Pycnogenol modulates apoptosis by suppressing oxidative stress and inflammation in high glucose-treated renal tubular cells. Food Chem Toxicol. 2011 Jun 12. [Epub ahead of print]

  78. Kim YJ, Kim YA, Yokozawa T. Protection against oxidative stress, inflammation, and apoptosis of high-glucose-exposed proximal tubular epithelial cells by astaxanthin.J Agric Food Chem. 2009 Oct 14;57(19):8793-7.

  79. Advani A, Gilbert RE. The endothelium in diabetic nephropathy. Semin Nephrol. 2012 Mar;32(2):199-207.

  80. Herzig S. Liver: a target of late diabetic complications. Exp Clin Endocrinol Diabetes. 2012 Apr;120(4):202-4.

  81. Shrestha P, Ghimire L. A review about the effect of life style modification on diabetes and quality of life. Glob J Health Sci. 2012 Oct 10;4(6):185-90.

  82. Sung K, Bae S. Effects of a regular walking exercise program on behavioral and biochemical aspects in elderly people with type II diabetes. Nurs Health Sci. 2012 Dec;14(4):438-45

Gerelateerde artikelen

Diabetische nierziekte behandelen via de darm-nier-as?
Vlees verbetert gezondheid niertransplantatiepatiënten
Positieve metabole effecten van gastric bypass verdwijnen snel
Myo-inositol: niet te vroeg tijdens de zwangerschap
Luteïne en zeaxanthine